PRMT5 and myelodysplastic syndrome: The remaining trials are evaluating the safety and efficacy of PRMT5 inhibition are in patients with advanced/metastatic solid tumors (Drug: PF-06939999; NCT03854227), Myelodysplastic Syndrome (MDS) and AML (Drug: GSK3326595; NCT03614728), and NHL/MDS (Drug: JNJ64619178; NCT03573310).